- Conditions
- Leukemia, Lymphocytic, Chronic
- Interventions
- SGN-40 (anti-huCD40 mAb)
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Miami, Florida • New York, New York + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- perifosine
- Drug
- Lead sponsor
- Daphne Friedman
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- AT-101
- Drug
- Lead sponsor
- Ascenta Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Lymphoma
- Interventions
- ipilimumab
- Biological
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Chronic Myeloid Leukemia
- Interventions
- Omacetaxine mepesuccinate
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Jacksonville, Florida • Atlanta, Georgia + 7 more
- Conditions
- Lymphoma, Small Intestine Cancer
- Interventions
- pegylated interferon alfa
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2001
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia, MALT Lymphoma, Follicular Lymphoma, Pediatric-Type Follicular Lymphoma, IRF4 Gene Rearrangement, EBV-Positive DLBCL, Nos, Burkitt Lymphoma, Plasmablastic Lymphoma, High-grade B-cell Lymphoma, Primary Cutaneous Follicle Center Lymphoma, Primary Effusion Lymphoma, Mantle Cell Lymphoma, DLBCL Germinal Center B-Cell Type, Primary Mediastinal Large B Cell Lymphoma, T-Cell/Histiocyte Rich Lymphoma, ALK-Positive Large B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Splenic Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Nodal Marginal Zone Lymphoma, HHV8-Positive DLBCL, Nos, Lymphoplasmacytic Lymphoma, Duodenal-Type Follicular Lymphoma
- Interventions
- SGR-1505
- Drug
- Lead sponsor
- Schrödinger, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 16
- States / cities
- Gilbert, Arizona • Newark, Delaware • Pompano Beach, Florida + 13 more
- Conditions
- CML, Chronic Phase, CML (Chronic Myelogenous Leukemia, CML - Philadelphia Chromosome, Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, Chronic Phase
- Interventions
- Bosutinib, Dasatinib, Imatinib, Nilotinib
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Leukemia, Lymphoma
- Interventions
- rituximab, fludarabine phosphate, pixantrone dimaleate
- Biological · Drug
- Lead sponsor
- CTI BioPharma
- Industry
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- rabbit anti-thymocyte globulin (ATG), therapeutic allogeneic lymphocytes, busulfan, fludarabine phosphate, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, methotrexate
- Biological · Drug · Procedure
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Accelerated Phase of Disease, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL, Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blastic Phase, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia, Previously Treated Myelodysplastic Syndrome, Primary Myelofibrosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Disease, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
- Interventions
- Belinostat, Azacitidine, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Madison, Wisconsin
- Conditions
- Hematologic Malignancies, Leukemia
- Interventions
- Triciribine
- Drug
- Lead sponsor
- Prescient Therapeutics, Ltd.
- Industry
- Eligibility
- Not listed
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Houston, Texas
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Quality of Life
- Interventions
- cognitive assessment, management of therapy complications, psychosocial assessment and care, quality-of-life assessment
- Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2010
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Leukemia
- Interventions
- imatinib mesylate
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2002
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Not listed
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2032
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Leukemia, Myelodysplastic Syndromes
- Interventions
- busulfan, cyclophosphamide, cyclosporine, cytarabine, methotrexate, allogeneic bone marrow transplantation, syngeneic bone marrow transplantation
- Drug · Procedure
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1987 – 2003
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Myelodysplasia
- Interventions
- human myeloid progenitor cells, G-CSF
- Biological · Drug
- Lead sponsor
- Cellerant Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 10
- States / cities
- La Jolla, California • San Francisco, California • Stanford, California + 7 more
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- ABT-263
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2022
- U.S. locations
- 6
- States / cities
- La Jolla, California • Boston, Massachusetts • Omaha, Nebraska + 3 more
- Conditions
- Chronic Myelogenous Leukemia, Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
- Interventions
- Asciminib (ABL001), Nilotinib, Imatinib, Dasatinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 326 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • Ann Arbor, Michigan • New York, New York + 3 more
- Conditions
- Anemia, Cancer Fatigue, Chronic Lymphocytic Leukemia, Fever, Infectious Disorder, Lymphadenopathy, Lymphocytosis, Night Sweats, Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Richter Syndrome, Secondary Malignant Neoplasm, Thrombocytopenia, Weight Loss
- Interventions
- Ex Vivo-activated Autologous Lymph Node Lymphocytes, Laboratory Biomarker Analysis
- Biological · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Splenic Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Nodal Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma, Refractory Splenic Marginal Zone Lymphoma, Refractory Waldenstrom Macroglobulinemia, Richter Syndrome, Waldenstrom Macroglobulinemia
- Interventions
- Ibrutinib, Idelalisib, Laboratory Biomarker Analysis, Pembrolizumab
- Drug · Other · Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Rochester, Minnesota
- Conditions
- Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
- Interventions
- Rituximab, Interleukin-2, Natural killer cells, Cyclophosphamide, Methylprednisolone, Fludarabine
- Drug · Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Not listed
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Leukemia, Leukemia, B-Cell, Chronic
- Interventions
- Dose Level 1, Dose Level 2, Dose Level 2- Fixed Dose
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chronic Myelogenous Leukemia
- Interventions
- Nexavar (Sorafenib, BAY43-9006)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- Portland, Oregon